Charles Schwab Investment Management Inc. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,404,883 shares of the company’s stock after acquiring an additional 202,863 shares during the period. Charles Schwab Investment Management Inc. owned 0.45% of Amneal Pharmaceuticals worth $11,689,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in Amneal Pharmaceuticals by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock valued at $493,000 after purchasing an additional 5,146 shares during the period. California State Teachers Retirement System raised its stake in Amneal Pharmaceuticals by 5.4% during the 1st quarter. California State Teachers Retirement System now owns 122,504 shares of the company’s stock valued at $742,000 after acquiring an additional 6,321 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Amneal Pharmaceuticals by 3.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 562,929 shares of the company’s stock worth $3,575,000 after acquiring an additional 16,392 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Amneal Pharmaceuticals by 3,279.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 228,917 shares of the company’s stock valued at $1,454,000 after purchasing an additional 222,144 shares during the last quarter. Finally, Hennessy Advisors Inc. purchased a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $8,818,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on AMRX. Truist Financial increased their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a research note on Friday, September 6th. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Finally, Piper Sandler lifted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $10.00.

Insider Activity

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ AMRX opened at $8.45 on Monday. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of -12.43 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 52 week low of $4.46 and a 52 week high of $9.48. The firm has a 50-day moving average price of $8.55 and a 200 day moving average price of $7.86.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.